Patrick Baeuerle (born 24 November 1957) is a German-based molecular biologist, immunologist, professor and a biopharmaceutical entrepreneur. Baeuerle is known for his work on tyrosine sulfation of proteins,[1] transcription factor NF-kappaB,[2] and the development of bispecific T-cell engaging antibodies for therapy of cancer.[3]
Patrick A. Baeuerle
Born
Patrick Alexander Baeuerle
(1957-11-24) November 24, 1957 (age 66)
Friedrichshafen, West Germany
Occupation(s)
Molecular biologist, Immunologist, Entrepreneur and professor
After his post-doctorate, Baeuerle led a research group at Gene Center in Martinsried, Germany. In 1993, he became the professor of molecular biology, and was and the chairman at the medical faculty of Freiburg University, Germany.[6]
Baeuerle is the co-founder of the companies, iOmx AG, Harpoon Inc,[12]TCR2 Inc,[10] Maverick Inc, and Cullinan LLC. He is one of the Managing directors at MPM capital, which is a Cambridge-based venture capital firm.[11][13]
Research Activitiesedit
Tyrosine Sulfationedit
In 1987, Baeuerle showed that tyrosine sulfation is a frequent modification of secretory proteins that is added in the trans-Golgi compartment.[14][1]
Transcription factor NF-kappaBedit
Baeuerle deciphered the canonical pathway by which transcription factor NF-kappaB is activated and first described inhibitory subunit I-kappaB and the p65/RelA subunit.[2][15] Baeuerle is said to be one of the inventors of the controversial NF-kappaB.[16][17] He along with his team showed that NF-kappaB is an oxidative stress-responsive transcription factor and described a functional role of NF-kappaB in the nervous system.[18][19]
Cancer Therapyedit
Baeuerle lead the development of BiTE antibody Blincyto® (blinatumomab; AMG 103)[20] which is approved by the US FDA for treatment of relapsed/refractory acute lymphoblastic leukemia.[21][22] He has invented various antibody-based constructs that are designed to engage cytotoxic T cells for lysis of cancer cells.[23]
Referencesedit
^ abBaeuerle, P A; Huttner, W B (1 December 1987). "Tyrosine sulfation is a trans-Golgi-specific protein modification". Journal of Cell Biology. 105 (6): 2655–2664. doi:10.1083/jcb.105.6.2655. PMC2114704. PMID 3121635.
^ abBaeuerle, P A; Henkel, T (April 1994). "Function and Activation of NF-kappaB in the Immune System". Annual Review of Immunology. 12 (1): 141–179. doi:10.1146/annurev.iy.12.040194.001041. PMID 8011280.
^Baeuerle, Patrick A.; Reinhardt, Carsten (15 June 2009). "Bispecific T-Cell Engaging Antibodies for Cancer Therapy". Cancer Research. 69 (12): 4941–4944. doi:10.1158/0008-5472.CAN-09-0547. PMID 19509221.
^WO 1989008147, Patrick A. Baeuerle, David Baltimore, Whitehead Institute For Biomedical Research, "ACTIVITION OF NF-kB PRECURSOR", published 1989-03-01
^Baeuerle, Patrick A.; Baltimore, David (April 1988). "Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor". Cell. 53 (2): 211–217. doi:10.1016/0092-8674(88)90382-0. PMID 3129195. S2CID 24771542.
^Hall, Stephen S. (23 November 1997). "Success Is Like a Drug". The New York Times.
^"Two Distinct Career Paths Offer Clear Choices". The Scientist. Retrieved 2017-10-04.
^"Reinventing the Antibody". The Scientist. Retrieved 2017-10-04.
^Perkel, Jeffrey (14 August 2008). "New Lymphoma Drug Shows Promise". Washington Post.
^ ab"TCR2 Therapeutics Unveils New Cancer Therapy Approach and $44.5M Round | Xconomy". Xconomy. 2016-12-08. Retrieved 2017-10-04.
^ ab"Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform". endpts.com. Retrieved 2017-10-04.
^Gormley, Brian (25 May 2017). "Harpoon Therapeutics Snares $45 Million Series B for Prostate Cancer Treatment". WSJ.
^"MPM Names Drug Developer Patrick Baeuerle Managing Director". Wall Street Journal. 13 March 2015.
^"Tyrosine sulfation of yolk proteins 1, 2, and 3 in Drosophila melanogaster (PDF Download Available)". ResearchGate. Retrieved 2017-10-04.
^Baeuerle, Patrick A.; Baltimore, David (28 October 1988). "IκB: a Specific Inhibitor of the NF-κB Transcription Factor". Science. 242 (4878): 540–546. Bibcode:1988Sci...242..540B. doi:10.1126/science.3140380. PMID 3140380. ProQuest 213535026.
^US 6410516, Baltimore, David; Sen, Ranjan & Sharp, Phillip A., "Nuclear factors associated with transcriptional regulation", published Jun 25, 2002
^"Patrick A. Baeuerle - Google Scholar Citations". scholar.google.de. Retrieved 2017-10-04.
^Schreck, Ralf; Albermann, Kaj; Baeuerle, Patrick A. (January 1992). "Nuclear Factor Kb: An Oxidative Stress-Responsive Transcription Factor of Eukaryotic Cells (A Review)". Free Radical Research Communications. 17 (4): 221–237. doi:10.3109/10715769209079515. PMID 1473734.
^Baeuerle, Patrick A.; Kufer, Peter; Bargou, Ralf (February 2009). "BiTE: Teaching antibodies to engage T-cells for cancer therapy". Current Opinion in Molecular Therapeutics. 11 (1): 22–30. PMID 19169956.
^Swaminathan, Nikhil (15 August 2008). "Antibody Drug Unleashes Tumor-Killer T Cells". Scientific American.
^Highfield, Roger (14 August 2008). "Patients 'free from cancer' after immune-boost treatment". The Telegraph.
^Baeuerle, Patrick A.; Reinhardt, Carsten (15 June 2009). "Bispecific T-Cell Engaging Antibodies for Cancer Therapy". Cancer Research. 69 (12): 4941–4944. doi:10.1158/0008-5472.CAN-09-0547. PMID 19509221.
External linksedit
University of Munich
Micromet, Inc.
University of Konstanz
Max-Planck Institute of Molecular Cell Biology and Genetics